Startups
Antibody Screening - Unravelling the full potential of entire immune repertoires (millions of B cells) VERAXA´s unique platform can combine the assessment of antibody binding with its functional capabilities in 1 single screening step, using a proprietary droplet-based microfluidic screening workstation
ADC Technology - Functionalizing UAA-antibodies with click chemistry
VERAXA‘s superior antibody labeling technologies allow conjugation of any given antibody at almost every position, to compete with the most prominent challenges in antibody-drug conjugate (ADC) and radioimmunoconjugates (RIC) drug development.
ADC Technology - Functionalizing UAA-antibodies with click chemistry
VERAXA‘s superior antibody labeling technologies allow conjugation of any given antibody at almost every position, to compete with the most prominent challenges in antibody-drug conjugate (ADC) and radioimmunoconjugates (RIC) drug development.
Overview
Location
Germany
Employees
11-50
Mentions in press and media 7
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Jun 12, 2026 | Veraxa Biotech goes public at NASDAQ | Through the transaction, VERAXA has established a strengthened financial position, including a USD 27.5 million senior secured note financing and a share purchase agreement of up to USD 50 million. The proceeds will support the continued a... |
| May 28, 2026 | Biotech companies Veraxa and Curatis strengthen financial positions | VERAXA Biotech AG aims to establish the premiere drug discovery and development engine for antibody drug conjugates and other novel antibody-based therapy concepts. The company’s pipeline currently comprises nine discovery and development ... |
| May 20, 2025 | VERAXA Biotech Appoints Rick Austin as Chief Scientific Officer | Industry Veteran to Support Acceleration of Key Pipeline Projects and Novel BiTAC™ Antibody Formats Towards Clinical Studies ZURICH, May 20, 2025 (GLOBE NEWSWIRE) -- VERAXA Biotech AG (“VERAXA”), an emerging leader in designing novel cancer... |
| May 5, 2025 | VERAXA Biotech Enters Co-discovery Alliance with OmniAb for a Novel Bispecific Antibody Drug Conjugate Program | Partnership Combines VERAXA's Proprietary ADC Technology with OmniAb's Antibody Discovery Technology for Novel Therapies Targeting Solid Tumors ZURICH, SWITZERLAND, May 05, 2025 (GLOBE NEWSWIRE) -- VERAXA Biotech AG (“VERAXA”), an emerging ... |
| Apr 23, 2025 | Veraxa plans to go public via SPAC at $1.64 billion valuation | VERAXA is a Swiss-based biopharmaceutical company advancing a premier drug discovery and development engine for ADCs and other novel antibody-based therapy concepts. The company originates from scientific discoveries made at the European M... |
| Jan 10, 2022 | Erste Kotierung am KMU-Segment der Schweizer Börse |
Reviews 0
FAQ about VERAXA Biotech GmbH
What has the press written about VERAXA Biotech GmbH?
Parsers VC has collected 7 articles mentioning VERAXA Biotech GmbH, among them “Veraxa Biotech goes public at NASDAQ” (Jun 12, 2026) and “Biotech companies Veraxa and Curatis strengthen financial positions” (May 28, 2026).
Is VERAXA Biotech GmbH still active?
Yes, VERAXA Biotech GmbH is active; its latest activity on Parsers VC dates from Jul 13, 2026.